The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While https://bronteahvh620029.oblogation.com/37971248/glp-3-retatrutide-a-comparative-analysis